|Articles|November 1, 2002

November 2002
Volume 8
Issue 11

Use of a Disease Severity Index for Evaluation of Healthcare Costs and Management of Comorbidities of Patients With Diabetes Mellitus

Author(s)James L. Rosenzweig, MD, Katie Weinger, EdD, Laurinda Poirier-Solomon, MPH

Download PDF: Use of a Disease Severity Index for Evaluation of Healthcare Costs and Management of Comorbidities of Patients With Diabetes Mellitus

Articles in this issue

almost 24 years ago

Article

Pill Splitting

almost 24 years ago

Article

Do Disease Management Programs for Patients With Coronary Heart Disease Make a Difference? Experiences of Nine Practices

almost 24 years ago

Article

Understanding Changes in Primary Care Clinicians' Satisfaction From Depression Care Activities During Adoption of Selective Serotonin Reuptake Inhibitors

almost 24 years ago

Article

State Regulation of Private Health Insurance: Prescription Drug Benefits, Experimental Treatments, and Consumer Protection

almost 24 years ago

Article

Antibiotic Resistance: The Iowa Experience

almost 24 years ago

Article

When Do Developing Countries Adopt Managed Care Policies and Technologies? Part I: Policies, Experience, and a Framework of Preconditions

almost 24 years ago

Article

Therapeutic Options for the Management of Type 2 Diabetes Mellitus

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Use of a Disease Severity Index for Evaluation of Healthcare Costs and Management of Comorbidities of Patients With Diabetes Mellitus

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps